[HTML][HTML] Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials …

SZ Pavletic, P Martin, SJ Lee, S Mitchell… - Biology of Blood and …, 2006 - Elsevier
The lack of standardized criteria for quantitative measurement of therapeutic response in
clinical trials poses a major obstacle for the development of new agents in chronic graft …

[HTML][HTML] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of clinical trials …

PJ Martin, D Weisdorf, D Przepiorka… - Biology of Blood and …, 2006 - Elsevier
The complexity of chronic graft-versus-host disease (GVHD) and the lack of established
research methods have made it difficult to design, conduct, and analyze clinical trials …

Guiding the optimal translation of new cancer treatments from canine to human cancer patients

C Khanna, C London, D Vail, C Mazcko… - Clinical cancer …, 2009 - AACR
Abstract On June 20, 2008, a meeting entitled “Translation of new cancer treatments from
canine to human cancer patients,” sponsored by the National Cancer Institute in Bethesda …

FDA drug approval summaries: oxaliplatin

A Ibrahim, S Hirschfeld, MH Cohen, DJ Griebel… - The …, 2004 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the safe and effective use of oxaliplatin in patients with metastatic carcinoma of the …

New models for large prospective studies: is there a better way?

TA Manolio, BK Weis, CC Cowie… - American journal of …, 2012 - academic.oup.com
Large prospective cohort studies are critical for identifying etiologic factors for disease, but
they require substantial long-term research investment. Such studies can be conducted as …

Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene

MH Cohen, S Hirschfeld, SF Honig, A Ibrahim… - The …, 2001 - academic.oup.com
This report summarizes information on drugs recently approved by the Food and Drug
Administration, Office of Drug Evaluation I, Division of Oncology Drug Products. Five …

Improving the value of clinical research through the use of Common Data Elements

J Sheehan, S Hirschfeld, E Foster, U Ghitza… - Clinical …, 2016 - journals.sagepub.com
The use of Common Data Elements can facilitate cross-study comparisons, data
aggregation, and meta-analyses; simplify training and operations; improve overall efficiency; …

H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen …

K Hamada, SL Gleason, BZ Levi… - Proceedings of the …, 1989 - National Acad Sciences
Transcription of major histocompatibility complex (MHC) class I genes is regulated by the
conserved MHC class I regulatory element (CRE). The CRE has two factor-binding sites …

[HTML][HTML] Global alignment of immunization safety assessment in pregnancy–the GAIA project

J Bonhoeffer, S Kochhar, S Hirschfeld, PT Heath… - Vaccine, 2016 - Elsevier
Immunization in pregnancy provides a promising contribution to globally reducing neonatal
and under-five childhood mortality and morbidity. Thorough assessment of benefits and risks …

Human Osteosarcoma Cell Lines Are Dependent on Insulin-like Growth Factor I for in Vitro Growth

CC Kappel, MC Velez-Yanguas, S Hirschfeld… - Cancer research, 1994 - AACR
Osteogenic sarcoma is the most common bone tumor of childhood and typically occurs
during the adolescent growth spurt when growth hormone and insulin-like growth factor I …